{"title":"异氧苄啶治疗类风湿性关节炎:与阿司匹林的双盲比较。","authors":"L S Gerlis, J M Gumpel","doi":"10.1093/rheumatology/20.1.50","DOIUrl":null,"url":null,"abstract":"<p><p>Nineteen patients with rheumatoid arthritis entered a double-blind cross-over study, comparing a new anti-inflammatory agent isoxepac, 200 mg three times daily, with aspirin 1.2 g three times daily. Eighteen patients completed 2-4 weeks treatment with each drug. The treatments were similar when assessed by measurement of joint pain, grip strength, morning stiffness, patients' global assessment and overall preference. Significantly fewer adverse effects were associated with isoxepac therapy when compared with aspirin therapy.</p>","PeriodicalId":76486,"journal":{"name":"Rheumatology and rehabilitation","volume":"20 1","pages":"50-3"},"PeriodicalIF":0.0000,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/20.1.50","citationCount":"3","resultStr":"{\"title\":\"Isoxepac in rheumatoid arthritis: a double-blind comparison with aspirin.\",\"authors\":\"L S Gerlis, J M Gumpel\",\"doi\":\"10.1093/rheumatology/20.1.50\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nineteen patients with rheumatoid arthritis entered a double-blind cross-over study, comparing a new anti-inflammatory agent isoxepac, 200 mg three times daily, with aspirin 1.2 g three times daily. Eighteen patients completed 2-4 weeks treatment with each drug. The treatments were similar when assessed by measurement of joint pain, grip strength, morning stiffness, patients' global assessment and overall preference. Significantly fewer adverse effects were associated with isoxepac therapy when compared with aspirin therapy.</p>\",\"PeriodicalId\":76486,\"journal\":{\"name\":\"Rheumatology and rehabilitation\",\"volume\":\"20 1\",\"pages\":\"50-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1093/rheumatology/20.1.50\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology and rehabilitation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/rheumatology/20.1.50\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology and rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rheumatology/20.1.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Isoxepac in rheumatoid arthritis: a double-blind comparison with aspirin.
Nineteen patients with rheumatoid arthritis entered a double-blind cross-over study, comparing a new anti-inflammatory agent isoxepac, 200 mg three times daily, with aspirin 1.2 g three times daily. Eighteen patients completed 2-4 weeks treatment with each drug. The treatments were similar when assessed by measurement of joint pain, grip strength, morning stiffness, patients' global assessment and overall preference. Significantly fewer adverse effects were associated with isoxepac therapy when compared with aspirin therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
